OncoMatch/Clinical Trials/NCT07086469
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Is NCT07086469 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant immunochemotherapy and Surufatinib Administration for toripalimab.
Treatment: Neoadjuvant immunochemotherapy · Surufatinib Administration · Concurrent Chemotherapy — The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage M1 (LIMITED TO SUPRACLAVICULAR LYMPH NODE METASTASIS)
Locally advanced, unresectable esophageal cancer...staged as T2-4, N0-3, M0-1 (M1 limited to supraclavicular lymph node metastasis).
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiotherapy
Cannot have received: surgery
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
anc ≥ 1.5 × 10⁹/l; platelet count ≥ 100 × 10⁹/l; hemoglobin ≥ 90 g/l
Kidney function
creatinine clearance ≥ 50 ml/min calculated by the cockcroft-gault formula
Liver function
total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07086469 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage M1 (LIMITED TO SUPRACLAVICULAR LYMPH NODE METASTASIS) is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages